Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Q Schmidt

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Nuclear Medicine|October 28, 2017
Absent Cerebellar Circulation With Intact Cerebral Blood Flow on a 99mTc Bicisate "Brain Death" StudyMatthew Q Schmidt, Frank V Schraml
World Journal of Nuclear Medicine|October 27, 2021
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/ computed tomography in the diagnosis of a rare mycotic aneurysm of the thoracic aorta in a patient with fever of unknown originMatthew Q Schmidt, Rola Altoos, Jennifer J Kwak
World Journal of Nuclear Medicine|September 14, 2019
Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumorMatthew Q Schmidt, Zachary Trenbeath, Bennett B Chin
Journal of Surgical Case Reports|February 1, 2018
Cervical left pulmonary arteryMatthew Q Schmidt, Michael Hafertepe, Randall Fortuna, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 26, 2019
Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular LymphomaAjay Major, Andrew Hammes, Matthew Q Schmidt, et al.
Oral Oncology|September 24, 2017
Predictors of survival in head and neck mucosal melanomaMatthew Q Schmidt, John David, Emi J Yoshida, et al.
Advances in Radiation Oncology|September 12, 2018
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancerCarlos E Vargas, Matthew Q Schmidt, Joshua R Niska, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Nuclear Medicine|October 28, 2017
Absent Cerebellar Circulation With Intact Cerebral Blood Flow on a 99mTc Bicisate "Brain Death" StudyMatthew Q Schmidt, Frank V Schraml
World Journal of Nuclear Medicine|October 27, 2021
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/ computed tomography in the diagnosis of a rare mycotic aneurysm of the thoracic aorta in a patient with fever of unknown originMatthew Q Schmidt, Rola Altoos, Jennifer J Kwak
World Journal of Nuclear Medicine|September 14, 2019
Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumorMatthew Q Schmidt, Zachary Trenbeath, Bennett B Chin
Journal of Surgical Case Reports|February 1, 2018
Cervical left pulmonary arteryMatthew Q Schmidt, Michael Hafertepe, Randall Fortuna, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 26, 2019
Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular LymphomaAjay Major, Andrew Hammes, Matthew Q Schmidt, et al.
Oral Oncology|September 24, 2017
Predictors of survival in head and neck mucosal melanomaMatthew Q Schmidt, John David, Emi J Yoshida, et al.
Advances in Radiation Oncology|September 12, 2018
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancerCarlos E Vargas, Matthew Q Schmidt, Joshua R Niska, et al.
Pageof 1